Pay in 4 interest-free payments of $7.23 Learn more
Ships within 48 hours · Estimated delivery Sep 27 - Oct 2
Phase 2 trial data (Jastreboff et al., NEJM 2023) demonstrated average weight reductions of approximately 1724% over 48 weeks notably higher than currently approved GLP-1 receptor agonists such as semaglutide, though direct comparisons are limited by differences in trial populations and designs
PubMed laboratory research record [PMID: 23766606] PubMed record related to this compound for laboratory literature review
Its all in the ingredients
Substantial weight reduction, regardless of the method, can lead to decreased bone mineral density, particularly at weight-bearing sites such as the hip and spine
US$ 29.45
US$ 22.46
US$ 23.56
US$ 28.92
US$ 25.18
US$ 24.50
US$ 23.97
US$ 22.16
US$ 21.23
